Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes
Shots:
- Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future
- Additionally- Biolojic is eligible to receive royalties on sales of therapies that emerges during the collaboration
- The collaboration will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel Ab-based therapy for diabetes
Ref: PRNewswire | Image: US News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com